4D pharma plc announced that Prof. Dr. med. Axel Glasmacher has been appointed as Non-Executive Chairperson of the Board, with immediate effect. Prof. Dr. med. Axel Glasmacher joined the Board of 4D Pharma as a Non-Executive Director in January 2019. Previously, he was Senior Vice President and Head of the Global Clinical Research and Development Hematology Oncology at Celgene, where he worked in various global roles for more than ten years. His work at Celgene led to the approvals of Revlimid®, Idhifa®, and Vidaza® (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn. David Norwood, the current Non-Executive Chairperson, will concurrently step down from this role but remains as a Non-Executive Director of 4D.